A combination of TLR9 and STING agonists induces potent neopeptide-specific T cell immunity and improves ICB efficacy in tumor models
American Association of Immunologists (AAI)
When new COVID-19 vaccines were first administered two years ago, public health officials found an increase in cases of myocarditis, an inflammation of the heart muscle, particularly among young males who had been vaccinated with mRNA vaccines. It was unclear, however, what exactly was causing this reaction.
The researcher discusses the findings in a new study on the efficacy and safety of fecal microbiota (REBYOTA™), the first microbiota-based live biotherapeutic approved by the US FDA used to prevent recurrent Clostridioides difficile infection in adults.
A study from Ann & Robert H. Lurie Children’s Hospital of Chicago found that parents with children who were not yet vaccinated against COVID-19 were most likely to vaccinate their child after reading the following hypothetical scenario.
Researchers from the University of Frieburg discovered that coordinated differentiation and changes in the metabolism of breast cancer stem cells make them invisible for the immune system.
Anyone newly diagnosed with Crohn’s disease probably has some anxiety about having a chronic ailment for which there’s no cure. A Penn State Health doctor talks about how treatments and medication offer reason for hope.
One of the biggest goals of immunotherapy is to reverse T cell exhaustion to boost the immune system’s ability to destroy cancerous cells. Researchers at Sanford Burnham Prebys studying melanoma have found a new way to make this happen.
The American Society for Investigative Pathology awards Stephen J. Galli, MD, the 2024 ASIP Gold-Headed Cane Award.
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers, and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. DDW2023 will take place May 6-9 in Chicago and showcase 3,100 abstracts and hundreds of lectures on the latest advances in GI research, clinical practice and technology.
Prostate cancer frequently metastasizes to the bone and is incurable. Moffitt Cancer Center researchers are working to identify new treatment options for this subset of patients. In a new article published today in Science Advances, a team of Moffitt scientists demonstrates that chimeric antigen receptor T-cell (CAR T) therapy is an effective antitumor approach in mouse models of bone metastatic prostate cancer.